Imaging axonal damage and repair in multiple sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to quantify differences in axonal integrity and organization between active and non-active multiple sclerosis patients over a two-year period. It utilizes advanced MRI techniques, including Neurite Orientation Dispersion and Density Imaging (NODDI) and Diffusion Kurtosis (DK), to assess the interplay between axonal damage and repair in living patients. The study will also validate imaging parameters against histopathological findings to enhance understanding of disease progression and response to therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria for patients:

* Patients may be diagnosed with:

  1. active RRMS (n=100): Relapsing-remitting course and \> 1 clinical relapse and/or signs of MRI activity (\> 1 Gd enhancing lesion) during the last year before study enrollment.
  2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and/or signs of MRI activity during the last year before study enrollment.
* Age 18-80 years old
* No other neurological or psychiatric disorder

Inclusion criteria for healthy controls:

* Age 18-80 years old
* No other neurological or psychiatric disorder

Exclusion Criteria for patients and healthy controls:

* Pregnancy
* Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).
* Inability to give consent

Where it's running

• University Hospital Basel, Department of Neurology
  Basel, Switzerland Recruiting

Study contacts

• Principal investigator: Cristina Granziera, Prof. Dr. med. — Department of Neurology, University Hospital Basel
• Study coordinator: Cristina Granziera, Prof. Dr. med.
• Email: cristina.granziera@usb.ch
• Phone: +41 61-32 85 665

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SUN-627 in non-active SPMS/PPMS: a Phase 2a test in adults

  This trial tests whether SUN-627 is safe and tolerable in adults with non-active primary or secondary progressive MS.

  Recruiting at 5 sites Phase 2 Sundance Biosciences, Inc. · Tampa, Florida and 6 other locations · NCT07840326

• Rocbrutinib in PRL-Positive Relapsing-Remitting MS

  This study tests whether Rocbrutinib can help people with relapsing-remitting MS who have paramagnetic rim lesions, compared to dimethyl fumarate.

  Recruiting Phase 2 Guangzhou Lupeng Pharmaceutical Company LTD. · Beijing, Beijing Municipality · NCT07776743

• QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases

  This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07526493

• TRX319 treatment for people with primary or secondary progressive multiple sclerosis

  This trial will test whether the experimental therapy TRX319, given with or without a short bendamustine pre-conditioning, is safe and can slow or improve disability in adults with primary or secondary progressive MS.

  Recruiting at 8 sites Phase 1/2 Tr1X, Inc. · La Jolla, California and 7 other locations · NCT07477639

• Can QSM MRI help tell MS from age-related brain changes in older adults

  This study tests whether an advanced MRI technique called QSM can better differentiate MS-related brain lesions from age-related or small vessel changes in people aged 50–70.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07444047

• BCD-281 versus ocrelizumab for relapsing-remitting multiple sclerosis

  This study tests whether BCD-281 works as well and is as safe as ocrelizumab for adults 18–55 with relapsing‑remitting multiple sclerosis.

  Recruiting Phase 3 Biocad · Nizhny Novgorod · NCT07321093

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.